Evolus (EOLS) Non-Current Debt (2018 - 2026)
Evolus' (EOLS) quarterly Non-Current Debt came in at $156.4 million in Q1 2026, up 28.41% YoY from $121.8 million in Q1 2025, and up 7.06% on a QoQ basis from $146.1 million in Q4 2025.
Evolus (EOLS) Non-Current Debt (2018 - 2026) Analysis & Trends
Evolus (EOLS) has 9 years of Non-Current Debt data on file, last reported at $156.4 million in Q1 2026.
- Quarterly Non-Current Debt rose 28.41% year-over-year to $156.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $156.4 million (up 28.41% YoY) and the FY2025 annual result came in at $146.1 million, up 20.24% from the prior year.
- Non-Current Debt climbed to $156.4 million in Q1 2026, from $146.1 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $156.4 million in Q1 2026 to a low of $71.4 million in Q1 2022.
- A 5-year average of $109.9 million and a median of $120.6 million in 2024 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt advanced 0.92% — and 2023, when it soared 67.45%.
- Tracing EOLS's Non-Current Debt over 5 years: stood at $71.9 million in 2022, then surged by 67.45% to $120.4 million in 2023, then grew by 0.95% to $121.5 million in 2024, then rose by 20.24% to $146.1 million in 2025, then increased by 7.06% to $156.4 million in 2026.
- The last three Non-Current Debt figures came in at $156.4 million (Q1 2026), $146.1 million (Q4 2025), and $145.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.31 Bn | 43.35 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.88 Bn | 40.22 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 32.22 Bn | 30.54 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.85 Bn | 17.96 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.96 Bn | 11.43 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 130.00 Mn |
| 10 | Evolus | 546.22 Mn | 501.05 Mn | 57.18 Mn | 156.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 156.74 Mn |
| Mar 31, 2026 | 156.41 Mn |
| Dec 31, 2025 | 146.10 Mn |
| Sep 30, 2025 | 145.78 Mn |
| Jun 30, 2025 | 145.48 Mn |
| Mar 31, 2025 | 121.81 Mn |
| Dec 31, 2024 | 121.51 Mn |
| Sep 30, 2024 | 121.21 Mn |
| Jun 30, 2024 | 120.92 Mn |
| Mar 31, 2024 | 120.64 Mn |
| Dec 31, 2023 | 120.36 Mn |
| Sep 30, 2023 | 95.09 Mn |
| Jun 30, 2023 | 94.83 Mn |
| Mar 31, 2023 | 72.05 Mn |
| Dec 31, 2022 | 71.88 Mn |
| Sep 30, 2022 | 71.71 Mn |
| Jun 30, 2022 | 71.55 Mn |
| Mar 31, 2022 | 71.38 Mn |
| Dec 31, 2021 | 71.22 Mn |
| Sep 30, 2020 | 73.97 Mn |